Recruiting NA INTERVENTIONAL 1-arm NCT06715839

Target-specific immunoPET Imaging of Digestive System Carcinoma

Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma

Sponsor: RenJi Hospital

Conditions Appendix Cancer Bile Duct Carcinoma Colon Cancer Digestive Cancer Digestive System Cancer Digestive System Carcinoma Digestive System Neoplasm Esophagus Cancer Gallbladder Carcinoma Liver Cancer Malignancy Pancreatic Cancer Rectum Cancer Small Intestine Cancer Stomach Cancer

Interventions [18F]F-RESCA-G5 [18F]F-RESCA-RB14 [18F]F-RESCA-RND20 [18F]F-RESCA-T4 [18F]F-RESCA-WWH347 [68Ga]Ga-DOTA-H2D3 [68Ga]Ga-NOTA-G5 [68Ga]Ga-NOTA-RND20 [68Ga]Ga-NOTA-T4 [68Ga]Ga-NOTA-WWH347

Updated 2 times since 2025 Last updated: Dec 25, 2025 Started: Dec 4, 2024 Primary completion: Sep 30, 2027 Completion: Sep 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Appendix Cancer and Bile Duct Carcinoma and is currently actively recruiting participants. RenJi Hospital leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Jan 2026 — Present [monthly]

Recruiting NA
Jan 2025 — Jan 2026 [monthly]

Recruiting NA

First recorded

Dec 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RenJi Hospital

Data source: RenJi Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China